Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02598895 · ClinicalTrials.gov registry record · Phase 2

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by University of Washington.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target
1
Study location

NCT02598895 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that has completed, run by University of Washington. The registered enrollment target is 14 participants, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02598895, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) and contains inactivated genes in the BRCA 1/2 pathway. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions Studied

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer Prostate Carcinoma Metastatic in the Bone PSA Progression Castration Levels of Testosterone

Interventions

  • DRUG Carboplatin
  • DRUG Docetaxel
  • OTHER Laboratory Biomarker Analysis

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2016-01-26
Est. Completion 2021-09-14
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02598895

The ClinicalTrials.gov registry entry for NCT02598895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (82% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT02598895 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT02598895 about?

NCT02598895 is a clinical study titled "Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway". This pilot clinical trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) and contains inactivated genes in the BRCA 1/2 pathway. Drugs used in che...

What is the current status of trial NCT02598895?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-01-26. Estimated completion is 2021-09-14.

What conditions does trial NCT02598895 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, PSA Progression.

What interventions are being tested in trial NCT02598895?

The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER).

Who is sponsoring clinical trial NCT02598895?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02598895 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Metastatic Prostate Carcinoma

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.